z-logo
Premium
Golden Vaterite as a Mesoscopic Metamaterial for Biophotonic Applications
Author(s) -
Noskov Roman E.,
Machnev Andrey,
Shishkin Ivan I.,
Novoselova Marina V.,
Gayer Alexey V.,
Ezhov Alexander A.,
Shirshin Evgeny A.,
German Sergei V.,
Rukhlenko Ivan D.,
Fleming Simon,
Khlebtsov Boris N.,
Gorin Dmitry A.,
Ginzburg Pavel
Publication year - 2021
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.202008484
Subject(s) - materials science , vaterite , mesoscopic physics , biocompatibility , metamaterial , photothermal therapy , nanotechnology , optoelectronics , photonics , composite material , physics , quantum mechanics , metallurgy , aragonite , calcium carbonate
Mesoscopic photonic systems with tailored optical responses have great potential to open new frontiers in implantable biomedical devices. However, biocompatibility is typically a problem, as engineering of optical properties often calls for using toxic compounds and chemicals, unsuitable for in vivo applications. Here, a unique approach to biofriendly delivery of optical resonances is demonstrated. It is shown that the controllable infusion of gold nanoseeds into polycrystalline sub‐micrometer vaterite spherulites gives rise to a variety of electric and magnetic Mie resonances, producing a tuneable mesoscopic optical metamaterial. The 3D reconstruction of the spherulites demonstrates the capability of controllable gold loading with volumetric filling factors exceeding 28%. Owing to the biocompatibility of the constitutive elements, “golden vaterite” paves the way to introduce designer‐made Mie resonances to cutting‐edge biophotonic applications. This concept is exemplified by showing efficient laser heating of gold‐filled vaterite spherulites at red and near‐infrared wavelengths, highly desirable in photothermal therapy, and photoacoustic tomography.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here